	US 12,084,430 B2
	Tricyclic urea compounds as JAK2 V617F inhibitors
Cooper Taylor, Kennett Square, PA (US); Yanran Ai, West Chester, PA (US); Chunhong He, Boothwyn, PA (US); Ke Zhang, Garnet Valley, PA (US); and Eddy W. Yue, Landenberg, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Mar. 16, 2023, as Appl. No. 18/122,323.
Claims priority of provisional application 63/396,826, filed on Aug. 10, 2022.
Claims priority of provisional application 63/320,909, filed on Mar. 17, 2022.
Prior Publication US 2023/0295124 A1, Sep. 21, 2023
Int. Cl. C07D 401/14 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07D 471/14 (2006.01)

CPC C07D 401/14 (2013.01)

12 Claims

1. A compound, which is methyl ((1R,3R)-3-(7-(3-fluoro-1-(methyl-d₃)-1H-pyrazol-4-yl)-8-(4-fluorophenyl)-3-(methyl-d₃)-2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(2)-yl)cyclopentyl)carbamate, or a pharmaceutically acceptable salt thereof.